基本信息
浏览量:2
职业迁徙
个人简介
Research
Lymphoma is a very complex disease with many different subtypes. Our research focuses mainly on non-Hodgkin’s lymphoma, especially the T and NK cell lymphoma which are more prevalent in Asia. Besides understanding the disease through the use of various types of sequencing methodologies, we have also developed patient derived xenograft (PDX) models which are highly relevant to clinical drug testing and development. The available PDXs is further coupled with humanized mouse model for relevant testing of immune related drugs. This capability allows us to further verify our discoveries at the genomic level, generating preclinical data and bringing the studies towards clinical trials. We are also in a good position to partner with pharmaceutical and diagnostic companies to develop drugs and biomarkers respectively. Using genomic approaches, we have discovered novel therapeutic targets in Natural Killer/T-cell lymphoma (NKTCL) and Monomorphic Epitheliotropic Intestinal T-cell lymphoma (MEITL)1,2,3, which allow us to develop novel drugs against the disease4. Recently, we have also discovered novel biomarkers of response to immune checkpoint inhibitors in NKTCL which will allow us to better select patients for this class of drugs5. In partnership with Lucence Diagnostics, we have successfully developed clinical grade assay for the detection of these biomarkers in our patients. We have also improved the accuracy of diagnosis of T-cell lymphoma with the eventual aim of improving treatment6,7. Using a germline approach, we have also successfully gained further insights into the pathobiology of these aggressive diseases8,9. Through various approaches, we will continue to understand this group of diseases and improve their clinical outcome10,11.
Lymphoma is a very complex disease with many different subtypes. Our research focuses mainly on non-Hodgkin’s lymphoma, especially the T and NK cell lymphoma which are more prevalent in Asia. Besides understanding the disease through the use of various types of sequencing methodologies, we have also developed patient derived xenograft (PDX) models which are highly relevant to clinical drug testing and development. The available PDXs is further coupled with humanized mouse model for relevant testing of immune related drugs. This capability allows us to further verify our discoveries at the genomic level, generating preclinical data and bringing the studies towards clinical trials. We are also in a good position to partner with pharmaceutical and diagnostic companies to develop drugs and biomarkers respectively. Using genomic approaches, we have discovered novel therapeutic targets in Natural Killer/T-cell lymphoma (NKTCL) and Monomorphic Epitheliotropic Intestinal T-cell lymphoma (MEITL)1,2,3, which allow us to develop novel drugs against the disease4. Recently, we have also discovered novel biomarkers of response to immune checkpoint inhibitors in NKTCL which will allow us to better select patients for this class of drugs5. In partnership with Lucence Diagnostics, we have successfully developed clinical grade assay for the detection of these biomarkers in our patients. We have also improved the accuracy of diagnosis of T-cell lymphoma with the eventual aim of improving treatment6,7. Using a germline approach, we have also successfully gained further insights into the pathobiology of these aggressive diseases8,9. Through various approaches, we will continue to understand this group of diseases and improve their clinical outcome10,11.
研究兴趣
论文共 166 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Leukemia & lymphomano. 11 (2023): 1-10
引用0浏览0WOS引用
0
0
CANCER RESEARCHno. 7 (2023)
引用0浏览0引用
0
0
Yi-Qi Li,Chun-Ling Luo,Jia-Xin Jiang,Shuai He,Yang Liu,Wen-Xin Yan,Yi Xia,Qian Cui,Ying Huang,Jing Quan Lim,Dachuan Huang, Izzah Nabilah Hussein,
Advanced science (Weinheim, Baden-Wurttemberg, Germany)no. 36 (2023): n/a-n/a
引用0浏览0WOS引用
0
0
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn